Nanosonics launches new share buyback of up to $40 million
Nanosonics (ASX: NAN), a global leader in infection prevention, has announced that its Board has approved a further on-market share buyback of up to $40 million in FY27, as part of its disciplined capital management strategy.
The move follows a $20 million share buyback completed in FY26. The decision reflects the Board and management’s confidence in the strength of the balance sheet and the long-term growth outlook for the business.
When big ASX news breaks, our subscribers know first
The financial strength behind the decision
The expanded buyback is underpinned by a cash-generative and net cash position that gives the company flexibility to both invest in growth and return capital to shareholders. Key figures disclosed alongside the announcement include:
- Cash generated in FY26, excluding the $20 million buyback: $13.6 million
- Cash balance: $155.2 million
- Debt free
For investors, the combination of positive cash generation and a substantial net cash position signals that the return of capital is not being funded at the expense of financial flexibility.
| Metric | Figure | What It Means for Investors |
|---|---|---|
| FY27 buyback approved | Up to $40M | Expands on the prior program, signalling Board confidence |
| FY26 buyback completed | $20M | Establishes a track record of capital returns |
| Cash balance | $155.2M | Provides capacity to invest and return capital |
| Cash generated (ex-buyback) | $13.6M | Demonstrates ongoing cash generation |
| Debt position | Nil (debt free) | Reduces financial risk and adds flexibility |
Michael Kavanagh, CEO and President
“Nanosonics enters FY27 in a strong financial position, supported by a robust balance sheet, strong cash generation and continued confidence in the long-term growth outlook for the business.”
Where the growth capital is going
Management framed the buyback as complementary to, rather than a substitute for, continued investment in growth. The company identified three strategic priorities it intends to fund alongside the capital return:
-
Continued growth of the trophon franchise
-
Commercialisation of the CORIS System in FY27
CORIS commercialisation milestones have been advancing simultaneously across Australia, the UK, and the US, with a second FDA 510(k) submission filed to expand the range of endoscope indications cleared for the system ahead of its targeted FY27 broader launch.
- Pursuing potential bolt-on acquisitions to further expand the portfolio
The capacity to both fund these growth initiatives and return capital to shareholders points to a level of financial maturity that many earlier-stage medical technology companies cannot match.
Understanding on-market share buybacks
An on-market share buyback is a process where a company purchases its own shares directly through trading on the stock exchange, in the same way any other buyer would.
Shares purchased under the program are cancelled, reducing the total number of shares on issue. With fewer shares outstanding, each remaining share represents a larger proportion of the company, which can support per-share value over time.
According to CEO and President Michael Kavanagh, the approach reflects the company’s current position. Given its capital position, expected cash generation and modest franking credit balance, management believes an on-market buyback represents “an attractive and efficient use of capital while maintaining the financial capacity to invest in the significant growth opportunities ahead.”
How the buyback will work
The mechanics and governance of the program follow standard, disciplined capital-management practice. Key procedural details include:
-
The buyback will be undertaken on-market, in the ordinary course of trading, within the limits permitted under the Corporations Act 2001.
-
An Appendix 3C reflecting the buyback value is to be lodged with the ASX, dated 25 August 2026.
-
The program may be varied, suspended, or terminated at any time depending on market conditions, share price, operational performance, and alternative capital deployment opportunities.
These provisions represent conventional safeguards that allow the Board to remain flexible should conditions change, rather than an indication of hesitation.
The investment takeaway
The announcement presents a balanced capital story: continued investment in growth, a return of capital to shareholders, and a debt-free balance sheet supporting both.
This sits within Nanosonics’ broader capital management framework, which focuses on maintaining a strong balance sheet while allocating capital to opportunities that maximise long-term shareholder value. The Board regularly assesses operating cash flow, investment requirements, balance sheet capacity, potential growth opportunities and prevailing market conditions.
Looking ahead, the disclosed priorities, commercialisation of the CORIS System in FY27, ongoing trophon growth, and potential bolt-on acquisitions, will be the key areas for investors to monitor as the company deploys its capital across both growth and returns.
For readers wanting to understand the transition from development to real-world deployment in more depth, our full explainer on the CORIS controlled market release covers the first UK hospital installation, the FDA 510(k) regulatory pathway, and what the FY27 commercialisation timeline means for Nanosonics as a portfolio diversification play.
Don’t Miss the Next Healthcare Stock Move
Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000 subscribers rely on Big News Blast to stay ahead of the market. Click the “Free Alerts” button to start receiving alerts the moment news breaks.